MedinCell S.A.
EPA:MEDCL.PA
17.6 (EUR) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | MedinCell S.A. |
Symbool | MEDCL.PA |
Munteenheid | EUR |
Prijs | 17.6 |
Beurswaarde | 511,960,170 |
Dividendpercentage | 0% |
52-weken bereik | 5.85 - 19 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Christophe Douat |
Website | https://www.medincell.com |
An error occurred while fetching data.
Over MedinCell S.A.
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)